Accéder au contenu
Merck

Enhancing osteogenic differentiation in adipose-derived mesenchymal stem cells with Near Infra-Red and Green Photobiomodulation.

Regenerative therapy (2023-11-30)
Daniella Da Silva, Anine Crous, Heidi Abrahamse
RÉSUMÉ

Worldwide, osteoporosis is the utmost predominant degenerative bone condition. Stem cell regenerative therapy using adipose-derived mesenchymal stem cells (ADMSCs) is a promising therapeutic route for osteoporosis. Photobiomodulation (PBM) has sparked considerable international appeal due to its' ability to augment stem cell proliferation and differentiation properties. Furthermore, the differentiation of ADMSCs into osteoblast cells and cellular proliferation effects have been established using a combination of osteogenic differentiation inducers and PBM. This in vitro study applied dexamethasone, β-glycerophosphate disodium, and ascorbic acid as differentiation inducers for osteogenic induction differentiation media. In addition, PBM at a near-infrared (NIR) wavelength of 825 nm, a green (G) wavelength of 525 nm, and the novel combination of both these wavelengths using a single fluence of 5 J/cm2 had been applied to stimulate proliferation and differentiation effectivity of immortalised ADMSCs into early osteoblasts. Flow cytometry and ELISA were used to identify osteoblast antigens using early and late osteoblast protein markers. Alizarin red Stain was employed to identify calcium-rich deposits by cells within culture. The morphology of the cells was examined, and biochemical assays such as an EdU proliferation assay, MTT proliferation and viability assay, Mitochondrial Membrane Potential assay, and Reactive Oxygen Species assay were performed. The Central Scratch Test determined the cells' motility potential. The investigative outcomes revealed that a combination of PBM treatment and osteogenic differentiation inducers stimulated promising early osteogenic differentiation of immortalised ADMSCs. The NIR-Green PBM combination did appear to offer great potential for immortalised ADMSC differentiation into early osteoblasts amongst selected assays, however, further investigations will be required to establish the effectivity of this novel wavelength combination. This research contributes to the body of knowledge and assists in the establishment of a standard for osteogenic differentiation in vitro utilising PBM.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Monoclonal Anti-COL1A1 antibody produced in mouse, clone 3G3, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-FGFR3 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-DMP1 antibody produced in mouse, clone 1D4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-BGLAP antibody produced in mouse, clone 2D4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-FGF23 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-BGN antibody produced in mouse, clone 4E1-1G7, purified immunoglobulin, buffered aqueous solution